Johnny Högberg new CEO of Flemingsberg Science

On 1st November, Johnny Högberg will take over as Chief Executive Officer of the Flemingsberg Science Foundation.

The Foundation’s task is to develop southern Stockholm where clinical care and research are already strongly established with world-leading Karolinska University Hospital, the Karolinska Institute, the Royal Institute of Technology (KTH), Södertörn University and several other academies. Flemingsberg Science will contribute to making the Stockholm region one of the five leading Life Science regions in the world.

Johnny Högberg comes from Skellefteå Science City, where he was CEO, and replaces Björn Varnestig, who is giving up his post as CEO in connection with his 65th birthday.

“I am really looking forward to taking on the role of CEO of Flemingsberg Science. The Stockholm region is a strong area of growth in Europe with high ambitions for Life Science in particular. The fact that the region has the stated goal of attracting the EU’s new Health Emergency Preparedness and Response Authority (HERA) is one of several examples of how these ambitions are expressed in practice,” says Johnny Högberg, incoming CEO of Flemingsberg Science.

The foundation’s Chair, Financial Region Councillor Irene Svenonius (M), is pleased with the recruitment of the new CEO.

“We want to improve conditions for growth and development in Flemingsberg and the surrounding area. This will take place in a broad collaboration between the academies, municipalities and the regional authority, with both healthcare and expanded public transport. To achieve our high goals of attracting new companies, EU authorities, headquarters, investments and research, we need people with Johnny’s experience and knowledge,” says Irene Svenonius.

Cluster Engine Flemingsberg – ERDF Project for Growth in Life Science

Flemingsberg is taking a significant step towards establishing itself as a central player in Life Science with the launch of the “Cluster Engine Life Science Flemingsberg” project. The project has been granted funding from the European Regional Development Fund and aims to strengthen the growth and establishment of small and medium-sized enterprises (SMEs) within the life science sector in the Stockholm region. The total project budget is €10.8 million for the years 2025–2027.

BioLamina Establishes Operations in Flemingsberg – A Key Player in ATMP Development

As the world’s first and only producer of laminins, the biotechnology company BioLamina has expanded its operations and chosen to establish part of its business in Flemingsberg. Using laminins, a protein that creates an optimal environment for cells to expand and/or differentiate, they are a key player in the development of ATMPs (Advanced Therapy Medicinal Products) in Sweden and globally.

BIO-Europe – A Conference for Future Medical Innovations

BIO-Europe is Europe’s largest partnering conference for the biotechnology, pharmaceutical, and life science industries. The conference serves as a meeting place where companies, researchers, investors, and other stakeholders in the industry can network, establish collaborations, and discuss business opportunities. The event is held annually in various European cities. This year, BIO-Europe took place in Stockholm from November 4th to 6th, where discussions included advanced cell and gene therapies as the medicine of the future.